Natera CEO Steven Leonard Sells Over $645,000 Worth of Company Stock By Investing.com

In a recent transaction, Steven Leonard, CEO and President of Natera, Inc. (NASDAQ:), a leader in personalized genetic testing and diagnostics, sold a significant amount of company stock. On September 16, Leonard divested shares in a series of transactions that resulted in a total sale value of more than $645,000.

The sale consisted of multiple blocks of shares sold at varying prices, with weighted average prices ranging from $126.6641 to $130.932 per share. Specifically, the transactions were executed within the following price ranges: some shares were sold between $126.35 and $126.8350, others between $127.41 and $128.40, a further set between $128.46 and $129.44, additional shares between $129.64 and $130.3450, and the final batch between $130.83 and $131.18. These sales were executed under a Rule 10b5-1 trading plan, which was adopted by Leonard on December 11, 2023.

The shares Leonard sold represent a decrease in his direct ownership of Natera stock, though the exact percentage of his remaining stake was not disclosed in the filing. After these transactions, Leonard still holds a significant number of shares, indicating a continued vested interest in the company’s performance.

Investors often keep an eye on insider sales because they can provide insight into executives’ perspectives on the company’s current valuation and future prospects. However, it’s important to note that insider transactions can be subject to different personal financial strategies and don’t necessarily signal changes in the company’s fundamentals.

Natera is a leader in genetic testing, offering a range of services including prenatal screening, cancer risk assessment and organ transplant monitoring. The company’s commitment to improving healthcare through genetic testing remains central to its strategy.

The details of these transactions are publicly available in the most recent SEC filings, providing transparency to investors and the broader market.

In other recent news, Natera Inc . has seen an increase in revenue and growth, with sequential revenue up 12% from the first quarter and up 58% year-over-year. The company has raised its full-year revenue guidance to approximately $1.5 billion, with gross margin expectations of 55%. These developments are accompanied by record testing volumes and an increase in average selling prices.

Ahead of the new Galaxy study results, Piper Sandler remains positive on Natera, reiterating an Overweight rating and a $150.00 price target. The firm recognizes Natera’s significant lead in the market, particularly with its cancer test, Signatera.

TD Cowen and Canaccord Genuity also maintained their Buy ratings on Natera shares, expressing optimism about the company’s prospects following presentations at the European Society for Medical Oncology conference. Notably, Natera’s Renasight test has received approval from the National Kidney Foundation for testing for chronic kidney disease.

These are some recent developments that highlight Natera’s strong market position and potential for further growth.

InvestingPro Insights

Natera, Inc. (NASDAQ:NTRA) has been showing significant market activity and attracting investors’ attention with its remarkable performance indicators. According to data from InvestingPro, Natera has a market cap of $15.74 billion, reflecting its significant presence in the genetic testing industry. Despite its lack of profitability over the past twelve months, with a price to earnings ratio of -52.52, the company’s revenue growth has been impressive, increasing by 46.13% over the past twelve months as of Q2 2024. This growth trend is further evidenced by a quarterly revenue growth of 58.13% in Q2 2024, highlighting the company’s expanding market reach and operational scale.

InvestingPro Tips highlights that Natera’s share price movements have been quite volatile, which may be important for investors looking for short-term trading opportunities or those concerned about market stability. Additionally, analysts do not expect the company to be profitable this year, although they have revised their earnings forecast upward for the coming period. This contrast of high revenue growth against a backdrop of expected unprofitability could indicate a more speculative investment with potential for future growth.

For investors looking for more detailed analysis and additional InvestingPro Tips, Natera currently has 14 on InvestingPro, including insights into stock price trends, liquidity and debt levels. These tips can provide deeper insight into the company’s financial health and market position, accessible at https://www.investing.com/pro/NTRA.

This article was generated with the support of AI and reviewed by an editor. For more information, please see our T&Cs.